Asymchem Q1 2026 Revenue Rises but Profit Edges Lower

An update from Asymchem Laboratories (Tianjin) Co., Ltd. Class H ( (HK:6821) ) is now available.

Asymchem Laboratories (Tianjin) Co., Ltd. reported its unaudited first-quarter 2026 results, showing operating revenue of RMB 1.80 billion, up 16.91% year-on-year, while net profit attributable to shareholders fell 6.82% to RMB 304 million and earnings per share slipped to RMB 0.84. Net profit after excluding non-recurring items declined 10.88%, but net cash flow from operating activities rose 17.21% to RMB 527 million, indicating stronger cash generation despite margin pressure.

The company stated that the figures were prepared under Chinese Accounting Standards and/or IFRS as required by the Shenzhen Stock Exchange, and confirmed by management and the board as true, accurate and complete. The board also highlighted that the data, though unaudited by independent auditors, had been reviewed by the audit committee, offering investors indicative insight into current operating trends and profitability dynamics heading into 2026.

The most recent analyst rating on (HK:6821) stock is a Hold with a HK$120.00 price target. To see the full list of analyst forecasts on Asymchem Laboratories (Tianjin) Co., Ltd. Class H stock, see the HK:6821 Stock Forecast page.

More about Asymchem Laboratories (Tianjin) Co., Ltd. Class H

Asymchem Laboratories (Tianjin) Co., Ltd. is a China-based pharmaceutical contract development and manufacturing organization serving global drug developers. Listed in Hong Kong and Shenzhen, it provides R&D and manufacturing services for active pharmaceutical ingredients and related products under both PRC and international accounting standards.

Average Trading Volume: 444,032

Technical Sentiment Signal: Buy

Current Market Cap: HK$47.27B

See more insights into 6821 stock on TipRanks’ Stock Analysis page.